Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

Marcus Remmers, a partner of the Planetary Health Investments team of Novo Holdings, the controlling shareholder of Novo ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...

Sen. Sanders claims that the CEOs of major generic drugmakers said they produce and sell Ozempic for less $100 a month.

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

COPENHAGEN: Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss ...